Fregonese, F; Ahuja, SD; Akkerman, OW; Arakaki-Sanchez, D; Ayakaka, I; Baghaei, P; Bang, D; Bastos, M; Benedetti, A; Bonnet, M; Cattamanchi, A; Cegielski, P; Chien, JY; Cox, H; Dedicoat, M; Erkens, C; Escalante, P; Falzon, D; Garcia-Prats, AJ; Gegia, M; Gillespie, SH; Glynn, JR; Goldberg, S; Griffith, D; Jacobson, KR; Johnston, JC; Jones-Lopez, EC; Khan, A; Koh, WJ; Kritski, A; Lan, ZY; Lee, JH; Li, PZ; Maciel, EL; Galliez, RM; Merle, CSC; Munang, M; Narendran, G; Nguyen, VN; Nunn, A; Ohkado, A; Park, JS; Phillips, PPJ; Ponnuraja, C; Reves, R; Romanowski, K; Seung, K; Schaaf, HS; Skrahina, A; Soolingen, DV; Tabarsi, P; Trajman, A; Trieu, L; Banurekha, VV; Viiklepp, P; Wang, JY; Yoshiyama, T; Menzies, D (2018) Comparison of different treatments for isoniazid-resistant tuberculosis: an individual patient data meta-analysis. The lancet Respiratory medicine, 6 (4). pp. 265-275. ISSN 2213-2600 DOI: https://doi.org/10.1016/S2213-2600(18)30078-X

Downloaded from: http://researchonline.lshtm.ac.uk/4647219/

DOI: 10.1016/S2213-2600(18)30078-X

Usage Guidelines

Please refer to usage guidelines at http://researchonline.lshtm.ac.uk/policies.html or alternatively contact researchonline@lshtm.ac.uk.

Available under license: http://creativecommons.org/licenses/by-nc-nd/2.5/
66 papers systematic review+ updated review (1990-Feb 2016)

Authors contacted for 74 databases

35 databases available

33 Datasets recoded and merged (6,424 subjects)

33 datasets (5,502 subjects) with adequate information

23 Datasets (4,740 patients) included in analyses of at least one study question

15 data sets (3,763 subjects) in which some received these regimens

15 data sets (2,174 subjects)

15 data sets (1,350 subjects)

1,218 subjects excluded

1315 excluded regimens; 274 LTFU

139 No DST; 51 no rifampin acquired resistance

137 97 Died; 727 other durations

131 1350 (H)REZ duration (Table 1, S3)

Success analysis

15 data sets (1,350 subjects)

763 excluded regimens; 302 LTFU

Mortality analysis

15 data sets (1,719 subjects):

251 vs 1350 for >=6(H)REZ-FQ

118 vs 1350 for >=6RE 1-3Z FQ

FQ added to (H)REZ (table 2-3, S4-S5)

15 data sets (3,763 subjects) in which some received these regimens

SM added to (H)REZ (tables 4, S6)

15 data sets (2,698 subjects)

15 data sets (1,494 subjects) :

221 vs 1160 for >=6(H)REZ-FQ

113 vs 1160 for >=6RE 1-3Z FQ

1369 excluded regimens; 345 LTFU

139 No DST; 51 no rifampin acquired resistance

143 died; 1208 others durations

39 Excluded:

4 : Did not meet inclusion criteria (No treatment info; or total number of patients <20)

24: Data not available (authors have moved; data lost, or damaged in storage)

1 : Cannot share data

10 : Cannot reach authors

2 Datasets (~350 subjects): Excluded because of missing information

Outcomes not reported

Extrapulmonary TB only

No treatment or 1 drug only

10 DB excluded (762 subjects): no subject with regimen of interest (Table S1b)

817 subjects excluded: no regimen of interest (Table S2b)

392 no DST; 65 no rifampin acquired resistance

1369 excluded regimens; 345 LTFU

139 No DST; 51 no rifampin acquired resistance

143 died; 1208 others durations

392 no DST; 65 no rifampin acquired resistance

1369 excluded regimens; 345 LTFU

139 No DST; 51 no rifampin acquired resistance

143 died; 1208 others durations

392 no DST; 65 no rifampin acquired resistance

1369 excluded regimens; 345 LTFU

139 No DST; 51 no rifampin acquired resistance

143 died; 1208 others durations

392 no DST; 65 no rifampin acquired resistance